Cellectar Biosciences Inc’s recently made public that its Chief Executive Officer CARUSO JAMES V acquired Company’s shares for reported $49900.0 on Jul 02 ’25. In the deal valued at $4.99 per share,10,000 shares were bought. As a result of this transaction, CARUSO JAMES V now holds 11,638 shares worth roughly $41780.42.
Then, Longcor Jarrod bought 10,000 shares, generating $49,900 in total proceeds. Upon buying the shares at $4.99, the Chief Operating Officer now owns 12,768 shares.
Before that, Kolean Chad J bought 5,000 shares. Cellectar Biosciences Inc shares valued at $24,950 were divested by the Chief Financial Officer at a price of $4.99 per share. As a result of the transaction, Kolean Chad J now holds 6,418 shares, worth roughly $23040.62.
A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early July with a ‘”an Outperform”‘ rating. ROTH Capital started covering the stock on September 13, 2019. It rated CLRB as “a Buy”.
Price Performance Review of CLRB
On Monday, Cellectar Biosciences Inc [NASDAQ:CLRB] saw its stock fall -10.25% to $3.59. Over the last five days, the stock has lost -16.32%. Cellectar Biosciences Inc shares have fallen nearly -94.13% since the year began. Nevertheless, the stocks have fallen -59.98% over the past one year. While a 52-week high of $66.00 was reached on 06/04/25, a 52-week low of $3.70 was recorded on 10/27/25.
Levels Of Support And Resistance For CLRB Stock
The 24-hour chart illustrates a support level at 3.43, which if violated will result in even more drops to 3.28. On the upside, there is a resistance level at 3.84. A further resistance level may holdings at 4.10.
How much short interest is there in Cellectar Biosciences Inc?
A steep rise in short interest was recorded in Cellectar Biosciences Inc stocks on 2025-10-15, growing by 71509.0 shares to a total of 0.16 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 84111.0 shares. There was a rise of 45.95%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 21, 2016 when Ladenburg Thalmann began covering the stock and recommended ‘”a Buy”‘ rating along with a $2.70 price target.
